山东大学耳鼻喉眼学报 ›› 2026, Vol. 40 ›› Issue (3): 7-15.doi: 10.6040/j.issn.1673-3770.0.2025.177
王敏,刘皓,姜露涵,谭立约,李文,付小龙
WANG Min, LIU Hao, JIANG Luhan, TAN Liyue, LI Wen, FU Xiaolong
摘要: 目的 腺相关病毒(adeno-associated virus, AAV)是基因治疗的重要载体。本研究旨在包装AAV-ie-Tnfaip8l2病毒,系统评估能否以AAV为载体实现Tnfaip8l2蛋白在耳蜗的原位过表达,并探索其在基因敲除小鼠模型内耳组织中的转导效率及对该基因敲除小鼠的听觉功能治疗效果。 方法 采用分子克隆技术构建重组表达载体AAV-ie-Tnfaip8l2。将AAV-ie衣壳质粒及辅助质粒共转染至 293T细胞中,进行病毒颗粒的组装和复制。通过超速离心和层析纯化获得高纯度、高滴度的重组腺相关病毒制剂。运用显微注射技术,经圆窗膜对Tnfaip8l2-/-新生鼠进行圆窗注射AAV-ie-Tnfaip8l2。待Tnfaip8l2-/-小鼠生长至35 d龄(典型听力损失显现期)时,通过听力检测、扫描电镜、免疫荧光等方法评估疗效。 结果 高滴度的AAV-ie-Tnfaip8l2病毒可成功包装用于耳蜗圆窗注射,以实现Tnfaip8l2基因在Tnfaip8l2-/-小鼠耳蜗原位高效过表达。听力学检测显示,与对照组相比,AAV-ie-Tnfaip8l2回补组小鼠Click、短纯音(4 k、8 k、12 k、16 k、24 k、32 k)以及DPOAE阈值降低(P<0.05,n=3);扫描电镜显示外毛细胞静纤毛束排列紊乱现象得到了明显的改善。 结论 本研究证实AAV-ie-Tnfaip8l2可通过圆窗注射实现Tnfaip8l2基因在小鼠耳蜗原位的高效表达,部分挽救Tnfaip8l2-/-小鼠的听力功能,为老年性耳聋的治疗方案提供新的实验依据。
中图分类号:
| [1] Pupo A, Fernández A, Low SH, et al. AAV vectors: the Rubik's cube of human gene therapy[J]. Mol Ther, 2022, 30(12): 3515-3541. doi:10.1016/j.ymthe.2022.09.015 [2] Hu mL, Edwards TL, O’Hare F, et al. Gene therapy for inherited retinal diseases: progress and possibilities[J]. Clin Exp Optom, 2021, 104(4): 444-454. doi:10.1080/08164622.2021.1880863 [3] He XJ, Urip BA, Zhang ZJ, et al. Evolving AAV-delivered therapeutics towards ultimate cures[J]. J Mol Med, 2021, 99(5): 593-617. doi:10.1007/s00109-020-02034-2 [4] Lv J, Wang H, Cheng XT, et al. AAV1-hOTOF gene therapy for autosomal recessive deafness 9: a single-arm trial[J]. Lancet, 2024, 403(10441): 2317-2325. doi:10.1016/S0140-6736(23)02874-X [5] Qi JY, Tan FZ, Zhang LY, et al. AAV-mediated gene therapy restores hearing in patients with DFNB9 deafness[J]. Adv Sci, 2024, 11(11): 2306788. doi:10.1002/advs.202306788 [6] Qi JY, Xu L, Zeng FG, et al. OTOF-related gene therapy: a new way but a long road ahead[J]. Lancet, 2025, 405(10481): 777-779. doi:10.1016/S0140-6736(25)00248-X [7] Sun GQ, Zheng YD, Fu XL, et al. Single-cell transcriptomic atlas of mouse cochlear aging[J]. Protein Cell, 2023, 14(3): 180-201. doi:10.1093/procel/pwac058 [8] Eshel M, Milon B, Hertzano R, et al. The cells of the sensory epithelium, and not the stria vascularis, are the main cochlear cells related to the genetic pathogenesis of age-related hearing loss[J]. Am J Hum Genet, 2024, 111(3): 614-617. doi:10.1016/j.ajhg.2024.01.008 [9] Ege T, Tao LT, North BJ. The role of molecular and cellular aging pathways on age-related hearing loss[J]. Int J Mol Sci, 2024, 25(17): 9705. doi:10.3390/ijms25179705 [10] Fu XL, Sun XY, Zhang LQ, et al. Tuberous sclerosis complex-mediated mTORC1 overactivation promotes age-related hearing loss[J]. J Clin Invest, 2018, 128(11): 4938-4955. doi:10.1172/JCI98058 [11] Fu XL, Li PP, Zhang LQ, et al. Activation of Rictor/mTORC2 signaling acts as a pivotal strategy to protect against sensorineural hearing loss[J]. Proc Natl Acad Sci USA, 2022, 119(10): e2107357119. doi:10.1073/pnas.2107357119 [12] Li W, Li YL, Guan YT, et al. TNFAIP8L2/TIPE2 impairs autolysosome reformation via modulating the RAC1-MTORC1 axis[J]. Autophagy, 2021, 17(6): 1410-1425. doi:10.1080/15548627.2020.1761748 [13] Li W, Li Y, Wang M, et al. TNFAIP8L2 maintains hair cell function and regulates age-related hearing loss via mTORC1 signaling[J]. Mol Ther, 2025, 33(7): 3036-3055. doi:10.1016/j.ymthe.2025.03.046 [14] Sun HH, Gong SY, Carmody RJ, et al. TIPE2, a negative regulator of innate and adaptive immunity that maintains immune homeostasis[J]. Cell, 2008, 133(3): 415-426. doi:10.1016/j.cell.2008.03.026 [15] Zhang LY, Chen X, Wang XL, et al. AAV-mediated gene cocktails enhance supporting cell reprogramming and hair cell regeneration[J]. Adv Sci, 2024, 11(29): 2304551. doi:10.1002/advs.202304551 [16] Andres-Mateos E, Landegger LD, Unzu C, et al. Choice of vector and surgical approach enables efficient cochlear gene transfer in nonhuman primate[J]. Nat Commun, 2022, 13(1): 1359. doi:10.1038/s41467-022-28969-3 [17] Fu XL, Wan PF, Lu L, et al. Peroxisome deficiency in cochlear hair cells causes hearing loss by deregulating BK channels[J]. Adv Sci, 2023, 10(20): 2300402. doi:10.1002/advs.202300402 [18] Lee YY, Ha J, Kim YS, et al. Abnormal cholesterol metabolism and lysosomal dysfunction induce age-related hearing loss by inhibiting mTORC1-TFEB-dependent autophagy[J]. Int J Mol Sci, 2023, 24(24): 17513. doi:10.3390/ijms242417513 [19] Tan FZ, Chu CF, Qi JY, et al. AAV-ie enables safe and efficient gene transfer to inner ear cells[J]. Nat Commun, 2019, 10(1): 3733. doi:10.1038/s41467-019-11687-8 [20] Chen Y, Xu ZY, Sun HX, et al. Regulation of CD8+ T memory and exhaustion by the mTOR signals[J]. Cell Mol Immunol, 2023, 20(9): 1023-1039. doi:10.1038/s41423-023-01064-3 [21] Costa Verdera H, Kuranda K, Mingozzi F. AAV vector immunogenicity in humans: a long journey to successful gene transfer[J]. Mol Ther, 2020, 28(3): 723-746. doi:10.1016/j.ymthe.2019.12.010 [22] Ivanchenko MV, Hathaway DM, Mulhall EM, et al. PCDH15 dual-AAV gene therapy for deafness and blindness in Usher syndrome type 1F models[J]. J Clin Investig, 2024, 134(23): e177700. doi:10.1172/jci177700 [23] Mingozzi F, Meulenberg JJ, Hui DJ, et al. AAV-1-mediated gene transfer to skeletal muscle in humans results in dose-dependent activation of capsid-specific T cells [J]. Blood, 2009, 114(10):2077-2086.doi:10.1182/blood-2008-07-167510 [24] Hinderer C, Katz N, Buza EL, et al. Severe toxicity in nonhuman Primates and piglets following high-dose intravenous administration of an adeno-associated virus vector expressing human SMN[J]. Hum Gene Ther, 2018, 29(3): 285-298. doi:10.1089/hum.2018.015 [25] Weber T. Anti-AAV antibodies in AAV gene therapy: current challenges and possible solutions[J]. Front Immunol, 2021, 12: 658399. doi:10.3389/fimmu.2021.658399 [26] Martins KM, Breton C, Zheng Q, et al. Prevalent and disseminated recombinant and wild-type adeno-associated virus integration in macaques and humans[J]. Hum Gene Ther, 2023: hum.2023.134. doi:10.1089/hum.2023.134 [27] Qi J, Fu X, Zhang L, et al. Current AAV-mediated gene therapy in sensorineural hearing loss [J]. Fundam Res, 2022, 5(1): 192-202.doi:10.1016/j.fmre.2022.08.015 [28] Lau SC, Grati M, Isgrig K, et al. Dual-AAV vector-mediated expression of MYO7A improves vestibular function in a mouse model of Usher syndrome 1B[J]. Mol Ther Methods Clin Dev, 2023, 30: 534-545. doi:10.1016/j.omtm.2023.08.012 [29] Liu SY, Song WQ, Xin JR, et al. NRN1 and CAT gene polymorphisms, complex noise, and lifestyles interactively affect the risk of noise-induced hearing loss[J]. Biomed Environ Sci, 2021, 34(9): 705-718. doi:10.3967/bes2021.098 |
| [1] | 王梦慧,黎奥,魏浩,姜玥,吴星光,李鹿晞,钱晓云. 乙型肝炎病毒致聋多机制与临床预警[J]. 山东大学耳鼻喉眼学报, 2026, 40(3): 110-114. |
| [2] | 王凯健,王威,陈雪生,樊春笋,何颖颖,黄冬玲,钱村慧,丁树军. 中性粒淋巴细胞比值与成年人听力损失及听力阈值的关系:基于NHANES数据库的横断面研究[J]. 山东大学耳鼻喉眼学报, 2026, 40(2): 18-28. |
| [3] | 张潇涵,朱立亚,肖雨,付小龙. 利用腺相关病毒AAV1探究顺铂诱导的血管纹损伤中Gasdermin D的作用机制[J]. 山东大学耳鼻喉眼学报, 2026, 40(2): 29-34. |
| [4] | 王暖,王欣阳,吉长皓,刘敏,高建刚,孙锦. 邻近标记技术对活体小鼠耳蜗毛细胞表面蛋白进行特异性标记[J]. 山东大学耳鼻喉眼学报, 2026, 40(1): 6-12. |
| [5] | 陶朵朵,史彬,赵云舒,李勇刚,刘济生. 年龄相关性听力损失患者前扣带回神经递质水平及其与听力水平关系的初步研究[J]. 山东大学耳鼻喉眼学报, 2025, 39(6): 31-39. |
| [6] | 张丽霞,李琳. 基于GEO数据库筛选年龄相关性听力损失关键基因的分析研究[J]. 山东大学耳鼻喉眼学报, 2025, 39(3): 104-114. |
| [7] | 张静祎,董湘依,牟亚魁,宋西成. 细胞焦亡在耳鼻咽喉科疾病中的研究进展[J]. 山东大学耳鼻喉眼学报, 2024, 38(4): 140-148. |
| [8] | 王欣怡,杨文杰,余文兴,徐艳红,胡纯红,母晓松,蒲晓兵,任建君,赵宇. 家庭化个体多元复合声治疗对耳鸣伴听力损失患者的疗效及影响因素分析[J]. 山东大学耳鼻喉眼学报, 2022, 36(6): 70-76. |
| [9] | 黄岚,高伟陈钢钢. 内耳疾病继发BPPV的发病机制和临床特征的研究进展[J]. 山东大学耳鼻喉眼学报, 2022, 36(4): 108-113. |
| [10] | 马宁, 陈敏, 刘薇, 杨扬, 邵剑波, 郝津生, 刘冰, 张晓, 段晓岷, 张祺丰, 张杰. 儿童颞骨骨折临床特点和治疗策略[J]. 山东大学耳鼻喉眼学报, 2022, 36(1): 13-19. |
| [11] | 胡春燕, 党攀红, 张睿, 樊孟耘. 儿童单侧感音性听力损失的听力学及影像学特征149例分析[J]. 山东大学耳鼻喉眼学报, 2022, 36(1): 31-36. |
| [12] | 周腊梅, 蒋雯, 刘稳, 乔月华. 持续性特发性耳鸣严重程度的相关因素分析[J]. 山东大学耳鼻喉眼学报, 2021, 35(6): 70-76. |
| [13] | 兰世鹏,陈智斌,曹新,邢光前. 一个新的X连锁耳聋综合征的表型特征[J]. 山东大学耳鼻喉眼学报, 2021, 35(3): 65-69. |
| [14] | 林宗通,沈翎,杨中婕. 腺样体大小及圆枕类型对儿童分泌性中耳炎的影响[J]. 山东大学耳鼻喉眼学报, 2020, 34(5): 121-126. |
| [15] | 丁玉静,兰兰,王秋菊,冀飞,熊芬,谢林怡,丁海娜,夏寅,赵辉. 外伤导致听力损失的临床特点及预后[J]. 山东大学耳鼻喉眼学报, 2020, 34(1): 9-14. |
|
||